AIM’s Latest Newsletter: The Research Edition, July 2023

Image

This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research.

This edition features:

  • Letter from AIM’s President, Sam Guild
  • Notes From the Lab: Novel Targets for Immune Checkpoint Inhibitors
    By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory
  • In Plain English: Neoadjuvant Therapy for Melanoma, and How We Got Here
    By Kim Margolin, M.D., FACP, FASCO
  • Clinical Trials Catch Up: An Interview with Joshua M.V. Mammen, M.D., Ph.D., F.A.C.S.
    By Alicia Rowell, Vice President, AIM at Melanoma

Recent Posts

Featured image for “Notes from the Lab: Novel targets for immune checkpoint inhibitors”
Sep. 17, 2023

Notes from the Lab: Novel targets for immune checkpoint inhibitors

Featured image for “Becoming a Melanoma Caregiver…Now What? PART III with guest host, Melissa Wilson, PA-C, MPAS, UPMC Hillman Cancer Center”
Sep. 12, 2023

Becoming a Melanoma Caregiver…Now What? PART III with guest host, Melissa Wilson, PA-C, MPAS, UPMC Hillman Cancer Center

Featured image for “In Plain English—Neoadjuvant Therapy for Melanoma, and How We Got Here”
Sep. 07, 2023

In Plain English—Neoadjuvant Therapy for Melanoma, and How We Got Here

Featured image for “Survivor Profile: Tricia Riffenburgh, Stage IV Melanoma”
Aug. 28, 2023

Survivor Profile: Tricia Riffenburgh, Stage IV Melanoma

Featured image for “Clinical Trials Catch Up”
Aug. 15, 2023

Clinical Trials Catch Up

Filter by Tag